Decline in the Value of Securities Due to Fluctuations in Interest Rates, Stock Prices, Bond Prices and Exchange Rates
First written in FY2016. 10 of 35 entries say "Worsened", first in FY2019-Q3. Latest entry: 2026-08-07.
FIDEA Holdings moved to the "Worse" side of this theme in 2016, 5 years before the typical company in this theme (2021).
The whole theme swung hardest in 2022: 9 of 14 companies on the "Worse" side.
7 other companies' latest entry also says "Mitigated".
- 2026-08-07MitigatedEarnings
「Other securities Valuation gains (losses) △22,088 △430 4,725」
Valuation losses on other securities narrowed from ¥26.813 billion at the end of the previous fiscal year to ¥22.088 billion. By contrast, valuation gains and losses on bonds deteriorated. - FY2026Decline in securities balances and market risk exposure, with valuation differences remaining negativeAnnual report
「In the markets division, while working to rebuild its portfolio with priority given to improving valuation gains and losses on securities, interest and dividend income on securities, gains and losses on Japanese government bonds and other bonds, and gains and losses related to stocks and other securities all declined year on year.」
Securities VaR declined from ¥30.8 billion at the end of the previous fiscal year to ¥25.6 billion, while the valuation difference on available-for-sale securities was negative ¥24,102 million, indicating that the improvement in valuation gains and losses remains a work in progress. - FY2026-H1MitigatedAnnual report
「Valuation difference on available-for-sale securities △23,415 △18,604 No impairment losses were recorded during the previous consolidated fiscal year or the interim consolidated accounting period.」
The negative valuation difference on available-for-sale securities narrowed, and no impairment losses on securities were recorded during the interim period. Some market-related losses improved from the end of the previous fiscal year. - FY2025-H1WorsenedAnnual report
「Valuation difference on available-for-sale securities △10,668 △16,513 Losses on sales of stocks and other securities ¥294 million ¥1,075 million」
The negative valuation difference on available-for-sale securities widened from the end of the previous fiscal year, and losses on sales of stocks and other securities also increased from the same period of the previous year. Meanwhile, it is stated that no impairment losses on securities were recorded during the interim period. - FY2024-Q3Lower losses on sales of stocks and other securities, but a deterioration in valuation differencesAnnual report
「Losses on sales of stocks and other securities ¥1,182 million ¥543 million No impairment losses were recorded during the nine-month consolidated accounting period.」
Losses on sales of stocks and other securities decreased from ¥1,182 million in the same period of the previous year to ¥543 million, and no impairment losses on securities were recorded. Meanwhile, the valuation difference on available-for-sale securities worsened from negative ¥4,458 million at the end of the previous fiscal year to negative ¥10,526 million, indicating differing movements among market-related indicators. - FY2024-Q2WorsenedAnnual report
「Impairment losses during the interim consolidated accounting period amounted to ¥29 million, including ¥29 million on stocks. Valuation difference on available-for-sale securities △14,975」
¥29 million in impairment losses on securities was recorded, and the valuation difference on available-for-sale securities worsened from negative ¥4,458 million at the end of the previous fiscal year to negative ¥14,975 million. - FY2024-Q1MaterialisedAnnual report
「Impairment losses during the first-quarter consolidated accounting period amounted to ¥32 million, including ¥32 million on stocks.」
¥32 million in impairment losses on securities was recorded in the first quarter. - FY2023-Q3WorsenedAnnual report
「Losses on sales of stocks and other securities ¥1,002 million ¥1,182 million」
Losses on sales of stocks and other securities increased from ¥1,002 million in the same period of the previous year to ¥1,182 million. Meanwhile, it is stated that no impairment losses on securities were recorded during the nine-month consolidated accounting period. - FY2023-Q2WorsenedAnnual report
「Losses on sales of stocks and other securities ¥537 million ¥950 million No impairment losses were recorded during the previous consolidated fiscal year or the interim consolidated accounting period.」
Losses on sales of stocks and other securities increased from ¥537 million in the same period of the previous year to ¥950 million. Meanwhile, no impairment losses on securities were recorded in either the previous fiscal year or the interim period. - FY2023-Q1Higher losses on sales of stocks and other securities, with no impairment lossesAnnual report
「Losses on sales of stocks and other securities ¥256 million ¥561 million No impairment losses were recorded during the previous consolidated fiscal year or the first-quarter consolidated accounting period.」
Losses on sales of stocks and other securities increased from ¥256 million in the same period of the previous year to ¥561 million. Meanwhile, no impairment losses on securities were recorded during either the previous consolidated fiscal year or the first quarter. - FY2022Lower markets division earnings and market risk exposureAnnual report
「In the markets division, earnings declined mainly from interest and dividend income on securities and gains and losses related to stocks and other securities, as the division managed its portfolio to secure future earnings in response to significant changes in interest-rate conditions and financial markets toward the end of the fiscal year.」
Markets division earnings decreased by ¥1,189 million year on year, while securities VaR declined from ¥31.5 billion at the end of the previous fiscal year to ¥27.9 billion. The disclosure indicates differing movements in market earnings and market risk indicators. - FY2022-Q3WorsenedAnnual report
「Losses on sales of stocks and other securities ¥400 million ¥1,002 million」
Losses on sales of stocks and other securities increased from ¥400 million in the same period of the previous year to ¥1,002 million. Meanwhile, it is stated that no impairment losses on securities were recorded during the previous consolidated fiscal year or the nine-month consolidated accounting period. - FY2022-Q2Higher losses on sales of stocks and other securities, with no impairment lossesAnnual report
「Losses on sales of stocks and other securities ¥271 million ¥537 million No impairment losses were recorded during the previous consolidated fiscal year or the interim consolidated accounting period.」
Losses on sales of stocks and other securities increased from ¥271 million in the same period of the previous year to ¥537 million, while no impairment losses on securities were recorded in either the previous fiscal year or the interim period. - FY2022-Q1MitigatedAnnual report
「No impairment losses were recorded during the previous consolidated fiscal year or the first-quarter consolidated accounting period.」
No impairment losses on securities were recorded in the first quarter. - FY2022-Q1Higher losses on sales of stocks and other securities, with no impairment lossesAnnual report
「Provision for loan losses ¥156 million ¥305 million Losses on sales of stocks and other securities ¥137 million ¥256 million」
Losses on sales of stocks and other securities increased from ¥137 million in the same period of the previous year to ¥256 million, while no impairment losses on securities were recorded during the first-quarter consolidated accounting period. - FY2021MitigatedAnnual report
「No impairment losses were recorded during the consolidated fiscal year. Losses on sales of stocks and other securities decreased from ¥1,978 million to ¥595 million, while securities VaR declined from ¥59.9 billion at the end of the previous fiscal year to ¥31.5 billion.」
No impairment losses on securities were recorded, and both losses on sales of stocks and other securities and fiscal year-end VaR declined from the previous fiscal year. Meanwhile, the markets division was working to restore its risk assets and rebuild its portfolio. - FY2021-Q3Lower losses on sales, with impairment losses on securities continuingAnnual report
「Losses on sales of stocks and other securities ¥803 million ¥400 million Impairment losses during the nine-month consolidated accounting period amounted to ¥7 million, including ¥7 million on stocks.」
Losses on sales of stocks and other securities decreased from ¥803 million in the same period of the previous year to ¥400 million, while ¥7 million in impairment losses on securities was recorded. Although some losses associated with market movements narrowed, impairment losses continued. - FY2021-Q2Losses on sales decreased, while impairment losses were recordedAnnual report
「Losses on sales of stocks and other securities ¥732 million ¥271 million Impairment losses during the interim consolidated accounting period amounted to ¥40 million, including ¥40 million on stocks.」
Losses on sales of stocks and other securities decreased from ¥732 million in the same period of the previous year to ¥271 million, while ¥40 million in impairment losses on securities was recorded. - FY2021-Q1MitigatedAnnual report
「There were no impairment losses during the nine-month period of the current consolidated fiscal year.」
No impairment losses on securities were recorded in the first quarter. Losses on sales of stocks and other securities also decreased from ¥241 million in the same period of the previous year to ¥137 million. - FY2020WorsenedAnnual report
「In the markets division, amid continued instability in financial markets toward the end of the fiscal year due to the spread of COVID-19, we actively moved to significantly reduce positions in risk assets, including stocks and REITs, to maintain the soundness of the securities portfolio. As a result, the markets division recorded approximately ¥3.8 billion in losses on sales in March 2020, comprising losses on sales of Japanese government bonds and other bonds, losses on sales of stocks and other securities, and losses on the management of money trusts.」
In response to instability in financial markets, the company significantly reduced its risk assets and recorded approximately ¥3.8 billion in losses on sales in the markets division in March 2020. Securities VaR at fiscal year-end was also ¥59.9 billion, up from ¥31.4 billion at the end of the previous fiscal year. - FY2020-Q3MitigatedAnnual report
「Losses on sales of shares and other securities ¥1,146 million ¥803 million No impairment losses were recorded during the previous consolidated fiscal year or the nine-month period of the current consolidated fiscal year.」
Losses on sales of stocks and other securities decreased from ¥1,146 million in the same period of the previous year to ¥803 million, and no impairment losses on securities were recorded. Some losses associated with market movements narrowed. - FY2020-Q2WorsenedAnnual report
「Losses on sales of shares and other securities ¥247 million ¥732 million」
Losses on sales of shares and other securities increased from ¥247 million in the same period of the previous year to ¥732 million, with losses related to market fluctuations reflected in interim results. No impairment losses on securities were recorded during the interim period. - FY2020-Q1WorsenedAnnual report
「Losses on sales of shares and other securities ¥119 million ¥241 million」
Losses on sales of shares and other securities increased from ¥119 million in the same period of the previous year to ¥241 million, with losses related to market fluctuations reflected in results for the first quarter. - FY2019WorsenedAnnual report
「Losses on sales of shares and other securities ¥272 million ¥1,342 million」
Losses on sales of shares and other securities increased from ¥272 million in the previous fiscal year to ¥1,342 million. In addition, securities VaR at the fiscal year-end rose from ¥23.3 billion to ¥31.4 billion, indicating increased losses and exposure related to market fluctuations. No securities impairment losses were recorded during the fiscal year. - FY2019-Q3WorsenedAnnual report
「Losses on sales of shares and other securities ¥120 million ¥1,146 million」
Losses on sales of shares and other securities increased from ¥120 million in the same period of the previous year to ¥1,146 million, with losses related to the market segment reflected in actual results. No securities impairment losses were recorded during the nine-month period of the current fiscal year. - FY2019-Q2MaterialisedAnnual report
「Interim consolidated accounting period (as of 30 September 2018) Classification Type Contract amount, etc. (¥ millions) Of which: amounts due after more than one year (¥ millions) Fair value (¥ millions) Valuation gains (losses) (¥ millions) Over-the-counter Forward foreign exchange contracts Sell contracts 63,490 —— △1,153 △1,153 Buy contracts 165 —— 5 5 Total ——— ——— △1,148 △1,148」
Valuation gains or losses on forward foreign exchange contracts totaled a loss of ¥1,148 million, with valuation losses arising from market fluctuations reflected in interim results. - FY2019-Q1MaterialisedAnnual report
「Consolidated ordinary expenses increased by ¥67 million, or 0.6%, year on year to ¥10,315 million, mainly due to an increase in losses on sales of Japanese government bonds and other bonds, despite efforts to reduce operating expenses.」
The increase in losses on sales of Japanese government bonds and other bonds was reflected in actual results as a factor behind higher quarterly ordinary expenses. No impairment losses on securities were recorded during the quarter. - FY2018MaterialisedAnnual report
「Impairment losses for the current consolidated fiscal year totaled ¥27 million, all of which related to shares.」
Impairment losses on securities due to changes in market prices and other factors totaled ¥27 million during the fiscal year. - FY2018-Q2MaterialisedAnnual report
「Total ——— ——— △2,448 △2,448」
Valuation gains or losses on forward foreign exchange contracts amounted to a loss of ¥2,448 million, with losses arising from market fluctuations reflected in actual results. Meanwhile, no impairment losses on securities were recorded during the interim accounting period. - FY2018-Q1MitigatedAnnual report
「There were no impairment losses during the nine-month period of the current consolidated fiscal year.」
No impairment losses on securities were recognized during the quarter, with no new impairment charges recorded against the ¥28 million recognized in the previous consolidated fiscal year. - FY2017MaterialisedAnnual report
「Impairment losses for the current consolidated fiscal year totaled ¥28 million, comprising ¥0 million on shares and ¥28 million on other securities.」
Full-year impairment losses on securities due to changes in market prices and other factors totaled ¥28 million. - FY2017-Q3MaterialisedAnnual report
「Impairment losses for the nine-month period of the current consolidated fiscal year totaled ¥61 million, comprising ¥33 million on shares and ¥28 million on other securities.」
Securities impairment losses totaled ¥61 million. Valuation gains or losses on forward foreign exchange contracts amounted to a loss of ¥5,279 million, with losses arising from market fluctuations reflected in actual results. - FY2017-Q2MaterialisedAnnual report
「Consolidated ordinary expenses increased by ¥1,586 million, or 8.0%, year on year to ¥21,351 million, mainly due to an increase in losses on sales of securities.」
The increase in losses on sales of securities was reflected in actual results as a factor behind higher ordinary expenses. - FY2017-Q1MaterialisedAnnual report
「Consolidated ordinary expenses increased by ¥996 million, or 10.5%, year on year to ¥10,474 million, mainly due to an increase in losses on sales of securities.」
The increase in losses on sales of securities was cited as a factor behind the year-on-year increase in ordinary expenses. - FY2016First statedAnnual report
「If the value of the securities held declines substantially due to fluctuations in interest rates, share prices, bond prices, foreign exchange rates or other factors, impairment losses or valuation losses may arise, adversely affecting the performance and financial condition of the Group.」
Market risks associated with securities are explicitly disclosed, including securities market risk exposure measured by VaR. Securities VaR at the fiscal year-end was reported at ¥49.7 billion.